Programme

Public Private Partnerships Boost Alzheimer's Disease Drug Discovery.

IMI Official Satellite Symposium of the AD/PD 2011 Conference,
9th March 2011, Barcelona Spain
Hall C

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00-8:30</td>
<td>Registration, Coffee and Welcome : Elisabetta Vaudano (Innovative Medicines Initiative, Belgium)</td>
</tr>
</tbody>
</table>
| 8:30-09:20| **Setting the Scene:**  
Rivka Ravid (Brainbank Consultants, The Netherlands): From Specimen to Biomarker? Harmonisation of Bio bank SOP's in the Discovery of Novel Candidate Biomarkers for Alzheimer's Disease (AD).  
Mony de Leon (Center for Brain Health NYU, USA): Biomarkers useful for detecting presymptomatic AD are also useful in revealing mechanisms of disease. |
| 9:20-10:25| **New European Research Models to Boost Progress in AD Research**  
Ejner K. Moltzen (Lundbeck, Denmark): Why IMI: the industrial perspective.  
Elisabetta Vaudano (IMI, Belgium): European Union Support (FP7) for Joint Programming Initiatives: the Joint Programming on Neurodegenerative Diseases, JPND |
| 10:25 - 10:35| Break |
| 10:35-11:45| **PharmaCog: Tackling the bottlenecks in AD Drug discovery**  
Mike O’Neil (Eli Lilly, United Kingdom): PharmaCog: AD Drug discovery from bench to bedside.  
Alexandra Auffret (Centre d’Investigation Clinique Hôpital de la Timone, France): Tools to improve decision making in drug development.  
Mike O’Neil (Eli Lilly, United Kingdom): Towards better clinical study designs.  
Jean Georges (Alzheimer Europe, Luxembourg): Bringing the patient’s perspective to drug discovery challenges. |
| 11:45-12:10| **Getting the broad picture: from Europe, to US and beyond**  
Marc Cantillon (CAMD, The Critical Path Institute, USA): Global regulatory qualification of biomarkers in AD |
| 12:10-12:25| General Discussion, Round Table |